Vandetanib Completed Phase 2 Trials for Metastatic / Hormone Refractory / Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00498797E3-Hormone Refractory Prostrate Cancer Taxotere Combination
NCT00757692Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
NCT00659438Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer